Worth noting: prasugrel was given at 3.75 mg daily, the Japanese maintenance dose, rather than the 10 mg dose commonly used in Europe and the US.

Relevant context when considering generalizability outside Japan.

Major bleeding (BARC 3 or 5):
5.6% vs 8.4%
HR 0.66 (95% CI 0.47–0.91)

Stent thrombosis and serious AEs appeared similar between groups.

www.nejm.org/doi/full/10....

Worth noting: single-arm, n=16. The pre-specified primary endpoint, coronary 68Ga-DOTATATE uptake, was not met. Enrolment closed at 16 of 20 planned because of a tracer shortage. The authors call the other findings exploratory and hypothesis-generating.

Also lower after 6 months: HbA1c −21.1 mmol/mol, weight −6.7 kg, and plasma IL-1RA, leptin, E-selectin, ICAM-1, CCL2, CCL11 and CXCL13. Bone marrow retention increased and correlated with weight loss.

How it was measured: blood (n=16) and sternal bone marrow aspirates (n=14) at baseline and after 6 months of semaglutide ≤2.0 mg weekly. Flow cytometry for monocytes and haematopoietic precursors; 68Ga-DOTATATE PET-CT for coronaries, bone marrow and spleen.

JAMA Cardiology editorial: the two leading causes remain poorly managed. BP is controlled in 23% of women and 18% of men with hypertension; about half with IHD receive proven secondary prevention. Data from low- and middle-income countries remain sparse.

doi.org/10.1001/jamacardio.2026.4084

NEJM editorial: benefit driven mainly by nonfatal MI and revascularisation. At 5 y, 55.6% still took atorvastatin; 19.4% on placebo had started a statin.

Healthy, adherence-selected participants; no data on stopping long-term statins.

nejm.org/doi/full/10.1056/NEJMe2611127

Event rates per 1000 person-years:
Major CV events 10.9 vs 15.5
Death, dementia or disability 21.6 vs 23.0

Musculoskeletal, hepatobiliary and diabetes-related AEs more common with atorvastatin.

nejm.org/doi/full/10.1056/NEJMoa2607314